NasdaqGM:RAPPPharmaceuticals
Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?
Rapport Therapeutics recently reported extended efficacy data for its epilepsy candidate RAP-219, showing meaningful seizure reductions and reinforcing the drug’s therapeutic profile, while a rival’s trial disappointed.
With further RAP-219 results scheduled for presentation at the 2026 American Academy of Neurology Annual Meeting, the company’s position in epilepsy drug development has gained fresh attention.
We’ll now examine how RAP-219’s extended efficacy data shapes Rapport...